ATE212359T1 - Neurotrophe peptide des aktivitätsabhängigen neurotrophen faktors - Google Patents

Neurotrophe peptide des aktivitätsabhängigen neurotrophen faktors

Info

Publication number
ATE212359T1
ATE212359T1 AT95935735T AT95935735T ATE212359T1 AT E212359 T1 ATE212359 T1 AT E212359T1 AT 95935735 T AT95935735 T AT 95935735T AT 95935735 T AT95935735 T AT 95935735T AT E212359 T1 ATE212359 T1 AT E212359T1
Authority
AT
Austria
Prior art keywords
neurotrophic
activity
present
peptides
dependent
Prior art date
Application number
AT95935735T
Other languages
English (en)
Inventor
Douglas E Brenneman
Iiiana Gozes
Original Assignee
Us Gov Health & Human Serv
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Ramot filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE212359T1 publication Critical patent/ATE212359T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT95935735T 1994-10-17 1995-10-16 Neurotrophe peptide des aktivitätsabhängigen neurotrophen faktors ATE212359T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/324,297 US6174862B1 (en) 1991-04-22 1994-10-17 Neurotrophic peptides of activity dependent neurotrophic factor
PCT/US1995/012929 WO1996011948A1 (en) 1994-10-17 1995-10-16 Neurotrophic peptides of activity dependent neurotrophic factor

Publications (1)

Publication Number Publication Date
ATE212359T1 true ATE212359T1 (de) 2002-02-15

Family

ID=23262985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95935735T ATE212359T1 (de) 1994-10-17 1995-10-16 Neurotrophe peptide des aktivitätsabhängigen neurotrophen faktors

Country Status (7)

Country Link
US (1) US6174862B1 (de)
EP (1) EP0797590B1 (de)
JP (1) JPH10509428A (de)
AT (1) ATE212359T1 (de)
AU (1) AU707838B2 (de)
DE (1) DE69525177T2 (de)
WO (1) WO1996011948A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0966533T3 (da) * 1997-02-07 2010-01-04 Us Gov Health & Human Serv Aktivitetsafhængig neurotrof faktor III (ADNF III).
US6613740B1 (en) 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US6933277B2 (en) 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US6649411B2 (en) * 1999-07-30 2003-11-18 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
US7384908B1 (en) * 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
EP1285000B1 (de) * 2000-05-31 2004-11-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
US20030166544A1 (en) * 2000-09-07 2003-09-04 Clark Abbot F. Use of ADNP for the treatment of glaucomatous optic neuropathy
WO2002092781A2 (en) * 2001-05-17 2002-11-21 Ceremedix, Inc. Peptide compounds for counteracting reactive oxygen species and free radicals
AU2002335750A1 (en) * 2001-09-12 2003-03-24 Ramot At Tel-Aviv University Ltd. Neurotrophic components of the adnf i complex
ES2526822T3 (es) 2002-01-31 2015-01-15 Andromeda Bio Tech Ltd. Péptidos hsp y análogos para la modulación de respuestas inmunes mediante células presentadoras de antígeno
US20040235747A1 (en) * 2003-01-02 2004-11-25 Ramot At Tel-Aviv University Ltd. Methods of treating and/or preventing autoimmune diseases
US7960334B2 (en) 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
US7148192B2 (en) * 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
JP4878551B2 (ja) * 2004-04-08 2012-02-15 貞和 相磯 運動ニューロン疾患治療薬
US7452867B2 (en) * 2005-03-23 2008-11-18 Ramot At Tel-Aviv University, Ltd. Use of ADNF polypeptides for treating peripheral neurotoxicity
TWI303567B (en) * 2005-12-20 2008-12-01 Ind Tech Res Inst Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same
CA2638827A1 (en) * 2006-02-24 2007-08-30 Illana Gozes Protection of the retina against laser injury by adnf peptides such as nap and sal
DE112007001030T5 (de) 2006-04-28 2009-02-26 Kagoshima University Amyloid-ß-Fibrillogenese-inhibierendes Peptid
WO2008084483A1 (en) 2007-01-11 2008-07-17 Ramot At Tel Aviv University Ltd. Novel therapeutics based on tau/microtubule dynamics
CN101848934A (zh) * 2007-08-24 2010-09-29 以色列特拉维夫大学拉莫特技术转移公司 使用nap样和sal样肽模拟物的神经保护
US8586548B2 (en) 2009-08-17 2013-11-19 Ramot At Tel-Aviv University, Ltd. NAP alpha-aminoisobutyric acid analog with neuroprotective activity
US20130053320A1 (en) 2010-02-12 2013-02-28 Ramot At Tel-Aviv University, Ltd. Treatment of anemia by adnp and adnf polypeptides
WO2012015910A2 (en) 2010-07-28 2012-02-02 Allon Therapeutics Inc. Use of adnf polypeptides for treating neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5135956A (en) * 1988-10-18 1992-08-04 The Regents Of The University Of California Method of using cytoprotective alcohols to treat neural disease and neural injury
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
AU667045B2 (en) * 1991-04-22 1996-03-07 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Activity-dependent neurotrophic factor
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them

Also Published As

Publication number Publication date
EP0797590A1 (de) 1997-10-01
DE69525177D1 (de) 2002-03-14
AU707838B2 (en) 1999-07-22
WO1996011948A1 (en) 1996-04-25
DE69525177T2 (de) 2003-01-02
JPH10509428A (ja) 1998-09-14
US6174862B1 (en) 2001-01-16
EP0797590B1 (de) 2002-01-23
AU3764195A (en) 1996-05-06

Similar Documents

Publication Publication Date Title
ATE212359T1 (de) Neurotrophe peptide des aktivitätsabhängigen neurotrophen faktors
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
WO1996006108A3 (en) Cyclic cs-1 peptidomimetics, compositions and methods of using the same
BR9713400A (pt) Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese.
DE69433562D1 (de) Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel
IL99912A0 (en) Cyclosporins,their preparation and pharmaceutical compositions containing them
IL112111A0 (en) Peptide derivatives and pharmaceutical compositions containing them
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
NZ326874A (en) 6-phenylpyridyl-2-amine derivatives
ZA963959B (en) Tetralin compounds with improved mdr activity
ZA956678B (en) Adenovirus comprising a gene encoding glutathione peroxidase
ZA951974B (en) Bradykinin antagonist peptides incorporating N-subsituted glycines
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
GB2367061A (en) Peptides
EP1032556A4 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
AU579593B2 (en) Novel peptides which are active on the central nervous system and have an action on the cholinergic system
CA2139652A1 (en) Thrombin-inhibitors
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
EP0917535A4 (de) Neuroaktive peptide
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
PL329219A1 (en) Application of benzonaphtene derivatives in production of drugs for treating nervous system diseases
MY115795A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them
NO954081L (no) Cytotoksisk faktor forbundet med disseminert sklerose, dens påvisning og kvantifisering
WO1998042746A3 (en) Synthetic saposin c-derived neurotrophic peptides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties